Polivy (Polatuzumab Vedotin-piiq) – DLBCL | DengYue Medicine

Polivy Application Scope

Polivy is an antibody–drug conjugate targeting CD79b, used in combination regimens to treat diffuse large B‑cell lymphoma (DLBCL).

Characteristics

• Ingredients: Polatuzumab Vedotin-piiq

• Properties:

  • ADC linking humanized anti‑CD79b IgG1 antibody to monomethyl auristatin E

  • Upon binding to CD79b on B cells

  • Internalized MMAE is released to disrupt microtubules and induce cell death

• Packaging Specification: Lyophilized powder in single‑dose vials: 30 mg or 140 mg

• Storage:

  • Store refrigerated 2–8 °C in original carton, protect from light

  • Do not freeze or shake

• Expiry Date:

  • Refer to the vial label and outer carton for the expiration date

  • Discard post-expiry

• Executive Standard: Follows FDA and EMA approvals under ATC code L01XC37

• Approval Number:

  • US: BLA 761121 (accelerated approval 2019, frontline expansion 2023)

  • EU: EU/1/19/1388/001 (140 mg) and EU/1/19/1388/002 (30 mg)

• Date of Revision: Last major label update: April 2023 (USPI)

• Manufacturer: Genentech, Inc. (Roche group)

Guidelines for the Use of Polivy

• Dosage and Administration:

  • Dose: 1.8 mg/kg IV infusion every 21 days for 6 cycles

    • With R‑CHP (frontline) or bendamustine + rituximab (relapsed/refractory)

  • Infusion duration: 90 min initially; may reduce to 30 min if tolerated

  • Premedication: antihistamine + antipyretic before each infusion

• Adverse Reactions:

  • Common (≥ 20%):

    • peripheral neuropathy, neutropenia, anemia

    • thrombocytopenia, fatigue, diarrhea, nausea, and infections

  • Serious:

    • infections (2.9% death), PML (~0.6%), tumor lysis syndrome, hepatotoxicity

• Contraindications: None specified; use under professional supervision only

• Precautions:

  • Monitor CBC and infection signs; administer prophylaxis for PJP and herpes

  • Assess neurologic status for neuropathy and any PML signs

  • Caution pregnancy:

    • Use effective contraception for women (≥ 3 months)

    • men (≥ 5 months) post-treatment

Polivy Interactions

• Drug Interactions:

  • Strong CYP3A inhibitors/inducers may alter MMAE exposure

  • Monitor accordingly

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.